Claritas Pharmaceuticals is developing R-107, a nitric oxide releasing molecule designed to treat vaccine-resistant COVID-19 infection. Nitric oxide is the immune system's first line of defense against viral infection. When a viral threat is present, white blood cells migrate to the area of infection and release a burst of nitric oxide that crosses into the infected cell to inactivate the virus. In COVID-19 infections, natural nitric oxide levels may not be sufficient to eradicate the virus. R-107 augments the body's natural release of nitric oxide to strengthen the body's ability to eliminate the virus. Unlike vaccine therapy, which may prove ineffective against new mutations, R-107 is engineered to treat all current and future mutant forms of COVID-19. Our scientific team has built a reputation for global leadership in basic science, drug development, and clinical medicine. Our expertise and professional network enable us to create groundbreaking opportunities that tackle drug development challenges. Claritas Pharmaceuticals is headquartered in San Francisco, CA. The Company has leased recently renovated 8,500 square feet of laboratory, office, and archival space in Beverly, Massachusetts, fully-equipped with state-of-the-art systems to carry out analytical, bioanalytical, and synthetic chemistry activities.